Underlying disease characteristics dictate anti-VEGF dosing interval

BOSTON — Relegation to a greater than 12-week anti-VEGF dosing regimen was correlated with absence of leakage at 52 weeks in patients treated for neovascular age-related macular degeneration, according to a subgroup analysis of the VIEW 1 and 2 studies.“The bottom line of this study is that there are some patients who are going to be able to be treated at 12 weeks dosing with aflibercept based on their underlying disease characteristics,” Anthony Joseph, MD, said at the American Society of Retina Specialists meeting.